Abbvie Stock News

AbbVie (ABBV) will grant Alvotech a non-exclusive license to Humira (adalimumab) patents effective July 1, 2023 as part of a resolution over litigation.

AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130m upfront payment with the potential for shareholders to receive additional contingent […] The post AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion appeared first on FinSMEs .

Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S. A, F. Hoffmann-La Roche Ltd. , GlaxosmithKline, Novartis AG, Pfizer Inc. , Teva Pharmaceuticals and CSL. Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S. A, F. Hoffmann-La Roche Ltd. , GlaxosmithKline, Novartis AG, Pfizer Inc. , Teva Pharmaceuticals and CSL.

Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca.

Major companies in the anti-infective drugs market include Gilead Sciences, GlaxosmithKline, Merck & Co. , Johnson & Johnson, Pfizer Inc. , AbbVie, Bayer AG, Mylan N. V. , Shionogi and F. Hoffmann-La Roche Ltd. Major companies in the anti-infective drugs market include Gilead Sciences, GlaxosmithKline, Merck & Co. , Johnson & Johnson, Pfizer Inc. , AbbVie, Bayer AG, Mylan N. V. , Shionogi and F. Hoffmann-La Roche Ltd.

Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd. Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd.

Major players in the gynecology drugs market are Hoffmann-La Roche Ltd. , Pfizer Inc. , Merck & Co. Inc. , Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc. , Lupin Pharmaceuticals Inc. and Ferring Holding SA. Major players in the gynecology drugs market are Hoffmann-La Roche Ltd. , Pfizer Inc. , Merck & Co. Inc. , Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc. , Lupin Pharmaceuticals Inc. and Ferring Holding SA.

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

Ardelyx Inc (NASDAQ: ARDX ) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1 . Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial opportunity is validated by Linzess and Trulance. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) and AbbVie Inc''s (NYSE: ABBV ) Linzess achieved $1 billion in sales in 2021, while Salix Pharmaceuticals'' Trulance achieved … Full story available on Benzinga.com

The stock is up so far this year.

EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO ), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients'' lives, announced the appointment of Jim Douglas as the Company''s new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix''s finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions during his tenure as CFO for the Company, including his strong leadership through Miromatrix''s IPO. He has played a vital role in enabling our growth and positioning us well for future financial stability," said Jeff Ross, P.h.D, Miromatrix CEO. "We appreciate his dedication and are excited that he will remain part of the Miromatrix team." "It has been a privilege to serve as Miromatrix''s CFO and to see the impact that we are making in fundamentally transforming bioengineered organs.

ROCKVILLE, Md., March 1, 2022 /PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible to receive up to $1.38 billion in additional development, regulatory and commercial milestones…